Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status-Reference-Cited by-同舟云学术

Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status

Published:2019-10-21 Issue:1 Volume:76 Page:41-49
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Tveito Marit^ORCID,Molden Espen,Høiseth Gudrun,Correll Christoph U.,Smith Robert Løvsletten

Funder

South-Eastern Norway Regional Health Authority

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-019-02768-0.pdf

Reference47 articles.

1. Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI (2003) Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry 11(6):648–657

2. Cohen CI, Meesters PD, Zhao J (2015) New perspectives on schizophrenia in later life: implications for treatment, policy, and research. Lancet Psychiatry 2(4):340–350. https://doi.org/10.1016/S2215-0366(15)00003-6

3. Kovacs G, Almasi T, Millier A, Toumi M, Horvath M, Koczian K et al (2018) Direct healthcare cost of schizophrenia - European overview. Eur Psychiatry 48:79–92. https://doi.org/10.1016/j.eurpsy.2017.10.008

4. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 72(12):1172–1181. https://doi.org/10.1001/jamapsychiatry.2015.1737

5. Talaslahti T, Alanen HM, Hakko H, Isohanni M, Hakkinen U, Leinonen E (2012) Mortality and causes of death in older patients with schizophrenia. Int J Geriatr Psychiatry 27(11):1131–1137. https://doi.org/10.1002/gps.2833

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-12

2. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics;The World Journal of Biological Psychiatry;2024-09

3. Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders;Pharmaceuticals;2023-04-17

4. Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype;European Journal of Clinical Pharmacology;2023-02-20

5. The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders;Frontiers in Psychiatry;2023-02-16